论文信息 - Controlling the Control Arm in Metastatic Castration-Resistant Prostate Cancer Trials: Best Standard of Care or the Minimum Standard of Care? - 字舞流文

Controlling the Control Arm in Metastatic Castration-Resistant Prostate Cancer Trials: Best Standard of Care or the Minimum Standard of Care?

B. Gyawali | F. Vera-Badillo | S. Van Wambeke

[1] M. Piccart,et al. Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring , 2021, ESMO open.

[2] F. Vera-Badillo,et al. Treatment and Patient Selection for Patients with Metastatic Castration-resistant Prostate After Progression on Docetaxel and Abiraterone/Enzalutamide: When to Play Your CARD and When to Do Your PARP. , 2021, European urology.

[3] V. Prasad,et al. Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration. , 2019, JAMA oncology.

[4] H. Miyake,et al. Comparative Assessment of Efficacies Between 2 Alternative Therapeutic Sequences With Novel Androgen Receptor‐Axis‐Targeted Agents in Patients With Chemotherapy‐Naïve Metastatic Castration‐Resistant Prostate Cancer , 2017, Clinical genitourinary cancer.